Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to see how well an imaging test, called 18FDCFPyL
prostate specific membrane antigen (PSMA) positron emission tomography (PET), can show the
extent of prostate cancer when comparing to 68Ga-PSMA-11 PET/CT (another type of diagnostic
scan for prostate cancer).